Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.72% to close at $0.34 with the total traded volume of 5.59 Million shares. Northwest Biotherapeutics (NWBO) announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $10 million.
The Company will sell to the investors approximately 28.6 million shares of common stock at a purchase price of $.35 per share resulting in gross proceeds to the Company of $10 million. The investors will also receive warrants to purchase up to approximately 14.3 million shares of common stock with an exercise price of $.35 per share and an exercise period of 5 years. The placement is expected to close on or about December 23, 2016, subject to satisfaction of customary closing conditions.
The firm has institutional ownership of 29.70%, while insider ownership included 30.22%. Its price to sales ratio ended at 38.13. NWBO attains analyst recommendation of 2.00 with week performance of -58.43%.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) [Trend Analysis] climbed reacts as active mover, shares an increase 0.08% to traded at $85.05 and the percentage gap between open changing to regular change was 0.13%. BioMarin Pharmaceutical Inc. (BMRN) recently reported that company has initiated a global Phase 3 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism. The first child enrolled in the study was at a site in Australia.
“Based on the positive results seen in our Phase 2 study, we look forward to continuing to investigate vosoritide,” said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin. “We are grateful to the children and their families, who have participated in the earlier study and are participating in this Phase 3 study.”
The firm’s current ratio calculated as 4.40 for the most recent quarter. The firm past twelve months price to sales ratio was 14.00 and price to cash ratio remained 14.13. As far as the returns are concern, the return on equity was recorded as -20.90% and return on investment was -4.20% while its return on asset stayed at -13.50%. The firm has total debt to equity ratio measured as 0.26.